In October 2026, CVS Health described a five-store Michigan pharmacist pilot, according to Reuters’ report of 23 October. The initiative remains an experiment; the report did not establish employer-plan savings or a nationwide rollout.

Evaluate the complete employee journey

Benefits purchasers should request a precise service specification before considering participation. It should identify the tasks performed, the professionals responsible, eligibility and any employee charge. The proposal should also show what happens after a result requires further attention, including who owns the referral and how completion is confirmed.

An access assessment could test booking, opening hours, language support and alternative channels. Employers should define the intended population before interpreting utilisation. A visit count alone would not show whether the service reaches employees who previously struggled to obtain support.

Set the evidence threshold in advance

A proposed pilot should distinguish operational measures from health and cost outcomes. Completed visits and successful hand-offs may help assess delivery. Claims about better health or lower expenditure require a suitable comparison, sufficient follow-up and an explanation of missing information and participant selection.

Privacy arrangements should specify the reporting an employer receives and the boundary around individual clinical information. Clinical, legal and procurement advisers would need to assess the actual service rather than rely on an announcement.

For multinational benefits teams, the model offers a question to explore locally. Professional roles, delivery arrangements and compatibility with existing benefits would need separate verification in each proposed market.

The useful next step is a documented evaluation protocol with clear decision criteria. That would allow employers to investigate a potentially convenient access route while reserving any broader purchasing commitment until the operating model and results have been demonstrated. These are proposed purchaser checks, not additional findings from the CVS experiment.